Detection of p53 Autoantibodies in Sera of Gastric Cancer Patients and Their Prognostic Relevance

References

• Crawford L V, Pim D C, Bulbrook R D. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 1982; 30: 403–8
   PubMed Web of Science ®Google Scholar
• Davidoff A M, Iglehart J D, Marks J R. Immune response to p53 is dependent upon p53/hsp70 complexes in breast cancers. Proc Natl Acad Sci USA 1992; 89: 3439–42
   PubMed Web of Science ®Google Scholar
• Wild C P, Ridanpaa M, Anttila S, Lubin R, Soussi T, Husgavfel‐Pursiainen K, et al. p53 antibodies in the sera of lung cancer patients: comparison with p53 mutation in the tumour tissue. Int J Cancer 1995; 64: 176–81
   PubMedGoogle Scholar
• Angelopoulou K, Diamandis E P, Sutherland D J A, Kellen J A, Bunting P S. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 1994; 58: 480–7
   PubMed Web of Science ®Google Scholar
• Schlichtholz B, Legros Y, Gillet D, Gaillard C, Marty M, Lane D, et al. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 1992; 52: 6380–4
   PubMed Web of Science ®Google Scholar
• Peyrat J P, Bonneterre J, Lubin R, Vanlemmens L, Fournier J, Soussi T. Prognostic significance of circulating p53 antibodies in patients undergoing surgery for locoregional breast cancer. Lancet 1995; 345: 621–2
   PubMed Web of Science ®Google Scholar
• Willsher P, Pinder S E, Robertson L, Nicholson R I, Ellis I O, Bell J A, et al. The significance of p53 autoantibodies in serum of patients with breast cancer. Anticancer Res 1996; 16: 927–30
   PubMed Web of Science ®Google Scholar
• Caro de Fromentel C, May‐Levin F, Mourisse H, Lemmerle J, Chandrasekaran K, May P. Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B‐cell lymphoma. Int J Cancer 1987; 39: 185–9
   PubMedGoogle Scholar
• Preudhomme C, Lubin R, Lepeppey P, Vanrumbeke M, Fenaux P. Detection of serum anti‐p53 antibodies and their connection with p53 mutations in myelodysplastic syndromes and acute myeloid leukemia. Leukemia 1994; 8: 1589–91
   PubMed Web of Science ®Google Scholar
• Lethinen T, Luostarinen T, Dillner J. Serum p53 accumulation and altered antibody response to Epstein‐Barr virus proteins precede diagnosis of haemopoietic malignancies of lymphoid origin. Br J Haematol 1996; 93: 104–10
   PubMedGoogle Scholar
• von Breveren M C, Hollstein M C, Cawley H M, De Benedetti V M G, Bennett W P, Liang L, et al. Circulating anti‐p53 antibodies in oesophageal cancer patients are found predominantly in individuals with p53 core domain mutations in their tumors. Cancer Res 1996; 56: 4917–21
   PubMedGoogle Scholar
• Trivers G E, De Benedetti V M G, Cawley H L, Caron G, Harrington A M, Bennett W P, et al. Anti‐p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. Clin Cancer Res 1996; 2: 1767–75
   PubMed Web of Science ®Google Scholar
• Winter S F, Minna J D, Johnson B E, Takahasha T, Gazdar A F, Carbon D P. Development of antibodies against p53 in lung cancer patients appears to be dependent upon the type of p53 mutation. Cancer Res 1992; 53: 4168–74
   Google Scholar
• Schlichtholz B, Tredaniel J, Lubin R, Zaleman G, Hirsch H, Soussi T. Analysis of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. Br J Cancer 1994; 69: 809–16
   PubMed Web of Science ®Google Scholar
• Guinee D G, Trivis W D, Trivers G E, De Benedetti V M G, Cawley H, Welsh J, et al. Gender comparison in human lung cancer: analysis of p53 mutations, anti‐p53 serum antibodies and c‐erg‐2 expression. Carcinogenesis 1995; 16: 933–1002
   Google Scholar
• Marxsen J, Schmiegel W, Roder C, Harder R, Juhl H, Henne‐Bruns D, et al. Detection of the anti‐p53 antibody response in malignant and benign pancreatic disease. Br J Cancer 1994; 70: 1031–4
   PubMedGoogle Scholar
• Winter S F, Sekido Y, Minna J D, McLntire D, Johnson B E, Gazdar A F, et al. Antibodies against autologous tumor cell proteins in patients with small cell lung cancer: association with improved survival. J Natl Cancer Inst 1993; 85: 2012–8
   PubMed Web of Science ®Google Scholar
• Bourhis J, Lubin R, Roche B, Koscielny S, Bosq J, Dubois I, et al. Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma. J Natl Cancer Inst 1996; 88: 1228–33
   PubMedGoogle Scholar
• Stephen C W, Helminen P, Lane D P. Characterisation of epitopes on human p53 using phage displayed peptide libraries: insight into antibody‐peptide interactions. J Mol Biol 1995; 248: 58–78
   PubMedGoogle Scholar
• Legros Y, Lacabanne V, ďAgay M F, Larsen C J, Pla M, Soussi T. Production of human p53 specific monoclonal antibodies and their use in immunohistochemical studies of tumor cells. Bull Cancer 1993; 80: 102–10
   PubMedGoogle Scholar
• Kalthoff H, Schmiegel W, Roeder C, Kasche D, Schmidt A, Lauer G, et al. p53 and K‐ras alterations in pancreatic epithelial cell lesions. Oncogene 1993; 8: 289–98
   PubMed Web of Science ®Google Scholar
• Lim B H, Soong R, Grieu F, Robbins P D, House A K, Iacopetta B J. p53 accumulation and mutation in human gastric carcinoma. Int J Cancer 1996; 69: 200–4
   PubMed Web of Science ®Google Scholar
• Hsieh L L, Hsieh J T, Wang L Y, Fang C Y, Chang S H, Chen T C. p53 mutation in gastric cancer from Taiwan. Cancer Lett 1996; 100: 107–13
   PubMedGoogle Scholar
• Imazeki F, Omata M, Nose H, Ohto M, Isono K. p53 gene mutations in gastric and esophageal cancer. Gastroenterology 1992; 103: 892–6
   PubMedGoogle Scholar
• Kim J H, Takahashi T, Chiba I, Park J G, Birrer M J, Roh J K, et al. Occurence of p53 gene abnormalities in gastric carcinoma tumors and cell lines. J Natl Cancer Inst 1991; 83: 938–3
   PubMedGoogle Scholar
• Momand J, Zambetti G P, Olson D C, George D, Levine A J. The mdm2 oncogene product forms a complex with the p53 proteine and inhibits p53 mediated transactivation. Cell 1992; 69: i237–45
   PubMedGoogle Scholar
• Wadayama B, Toguchida J, Yamaguchi T, Sasaki M S, Kotoura Y, Yamamuro T. P53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas. Br J Cancer 1993; 68: 1134–9
   PubMed Web of Science ®Google Scholar
• Martin H M, Filipe M I, Morris R W, Lane D P, Sivestre F. p53 expression and prognosis in gastric carcinoma. Int J Cancer 1992; 50: 859–62
   PubMed Web of Science ®Google Scholar
• Kakeji Y, Korenaga D, Tsujitani S, Baba H, Anai H, Maehara Y, et al. Gastric cancer with p53 overexpression has high potential for metastasising to lymph nodes. Br J Cancer 1993; 67: 589–93
   PubMedGoogle Scholar
• Hurlimann J, Saraga E P. Expression of p53 protein in gastric carcinomas. Association with histologic type and prognosis. Am J Surg Pathol 1994; 18: 1247–53
   PubMedGoogle Scholar
• Gabbert H E, Muller W, Schneiders A, Meier S, Hommel G. The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma. Cancer 1995; 76: 720–6
   PubMed Web of Science ®Google Scholar
• Starzynska T, Markiewski M, Domagala W, Marlicz K, Mietkiewski J, Roberts S A, et al. The clinical significance of p53 accumulation in gastric carcinoma. Cancer 1996; 77: 2005–12
   PubMed Web of Science ®Google Scholar
• Joypaul B V, Hopwood D, Newman E L, Quereshi S, Grant A, Ogston S A, et al. The prognostic significance of the accumulation of p53 tumor suppressor gene protein in gastric adenocarcinoma. Br J Cancer 1994; 69: 943–6
   PubMed Web of Science ®Google Scholar
• Volkmann M, Muller M, Hofmann W J, Meyer M, Hagelstein J, Rath U, et al. The humoral immune response to p53 in patients with hepatocellular carcinoma is specific for malignancy and independent of the alpha‐fetoprotein status. Hepatology 1993; 18: 559–65
   PubMed Web of Science ®Google Scholar
• Trivers G E, Cawley H L, De Benedetti V M G, Hollstein M, Marion M J, Bennet W P, et al. Anti‐p53 antibodies in sera of workers occupationally exposed to vinyl chloride. J Natl Cancer Inst 1995; 87: 1400–7
   PubMedGoogle Scholar
• Lubin R, Zalcman G, Bouchet L, Tredaniel J, Legros Y, Cazals D, et al. Serum p53 antibodies as early markers of lung cancer. Nature ‘Med’ 1995; 1: 701–2
   PubMed Web of Science ®Google Scholar